L-Carnitine[Levocarnitine; Carnitor]
Compound snapshot
Class
Amino-acid derivative (not a peptide)
FDA approved
Levocarnitine is approved for carnitine deficiency
Clinical development
Approved
Last reviewed
September 2026
Research areas
Metabolism / Body weight / Mitochondrial function
Regulatory status
FDA-approved for carnitine deficiency — not a peptide
Internet attention
Moderate
Registry query
L-Carnitine
A naturally occurring amino-acid derivative, not a peptide. Prescription levocarnitine treats specific primary and secondary carnitine deficiencies; supplement products are also widely sold for unapproved fitness and weight-loss claims.
Reality check — what we actually know
Supported by human evidence
- This compound has completed human trials in at least one approved indication — see the regulatory section for what was actually approved.
Animal research only
- Corrects documented primary or secondary carnitine deficiency — its established medical use
- Supports normal mitochondrial fatty-acid transport when body stores are deficient
- May help selected dialysis or inherited-metabolic-disease patients under specialist care
Mechanistically plausible
- Carries long-chain fatty acids across the inner mitochondrial membrane so they can undergo beta-oxidation and contribute to energy production, especially in skeletal and heart muscle. More carnitine does not automatically increase fat loss when a person is not deficient.
Common internet claims
- Online discussion frequently presents L-Carnitine as a proven treatment rather than a research compound.
Not established
- Human efficacy for the outcomes commonly claimed
- Optimal route, quantity and duration in humans
- Long-term human safety
Evidence distribution
Each band is a live PubMed search for L-Carnitine, filtered to that kind of study. Top is the strongest evidence; the base is reasoning, not proof. A band with no records means that kind of study has not been published for this compound yet.
Mechanism and reported findings
Carries long-chain fatty acids across the inner mitochondrial membrane so they can undergo beta-oxidation and contribute to energy production, especially in skeletal and heart muscle. More carnitine does not automatically increase fat loss when a person is not deficient.
- Corrects documented primary or secondary carnitine deficiency — its established medical use
- Supports normal mitochondrial fatty-acid transport when body stores are deficient
- May help selected dialysis or inherited-metabolic-disease patients under specialist care
- Studies of routine supplementation for weight loss, energy and exercise performance show mixed and generally modest results
Strength of the evidence: High-quality regulatory evidence supports prescription levocarnitine for defined deficiency syndromes. Evidence is much weaker and inconsistent for fat loss or performance in people with normal carnitine status.
Safety and known cautions
Prescription and supplement uses are not equivalent. It can cause nausea, cramps, diarrhoea and a fishy body odour; seizure risk may increase in susceptible people. Kidney disease, dialysis and inherited metabolic disorders require clinician-directed care.
Evidence at a glance
No single score, on purpose. The line beside each bar shows how much reported outcomes vary between studies.
Development stage
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
- Regulatory review
- ApprovedCurrent